Indivior PLC (INDV)
 NASDAQ: INDV · Real-Time Price · USD
 31.20
 +1.83 (6.23%)
  At close: Nov 3, 2025, 4:00 PM EST
31.01
 -0.19 (-0.61%)
  Pre-market: Nov 4, 2025, 8:32 AM EST
Indivior Revenue
Indivior had revenue of $314.00M in the quarter ending September 30, 2025, with 2.28% growth. This brings the company's revenue in the last twelve months to $1.18B, down -0.17% year-over-year. In the year 2024, Indivior had annual revenue of $1.19B with 8.69% growth.
Revenue (ttm) 
 $1.18B
Revenue Growth 
 -0.17%
P/S Ratio 
 3.32
Revenue / Employee 
 $1,122,740
Employees 
 1,051
Market Cap 
3.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 95.00M | 8.69% | 
| Dec 31, 2023 | 1.09B | 192.00M | 21.31% | 
| Dec 31, 2022 | 901.00M | 110.00M | 13.91% | 
| Dec 31, 2021 | 791.00M | 144.00M | 22.26% | 
| Dec 31, 2020 | 647.00M | -138.00M | -17.58% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
INDV News
- 1 day ago - Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine - PRNewsWire
 - 4 days ago - Indivior PLC (INDV) Q3 2025 Earnings Call Transcript - Seeking Alpha
 - 5 days ago - Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance - PRNewsWire
 - 6 days ago - Indivior to Participate in the Stifel 2025 Healthcare Conference - PRNewsWire
 - 18 days ago - Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th - PRNewsWire
 - 20 days ago - Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment - PRNewsWire
 - 4 weeks ago - UK's Indivior to re-domicile to US after listing move - Reuters
 - 4 weeks ago - Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation - PRNewsWire